Advertisement

Chemotherapy pp 387-404 | Cite as

Potentiation of Drugs Using Sequential Chemotherapy Against Disseminated Breat, Bronchial and Central Nervous System Solid Tumors

  • P. Pouillart
  • L. Schwarzenberg
  • J. L. Amiel
  • G. Mathé
  • P. Huguenin
  • Ph. Morin
  • A. Baron
  • Ch. Laparre
  • R. Parrot
Part of the Chemotherapy book series (CT, volume 8)

Abstract

The role of chemotherapy in the treatment of solid tumors remains imprecise, chemotherapy is only used when other treatments have been tried and have failed, such as surgery and/or radiotherapy. This limitation of chemotherapeutic indications to the only palliation of advanced tumors might explain the inconstancy of its results. An important toxicity is often the price to pay for a greater efficiency, sought by applying several drugs, the choice, the association and the administration methods of which are often empirical (2, 3, 24). We have been trying to determine a chemotherapeutic protocol for patients suffering from solid tumors, in accordance with what we consider as the association chemotherapy principles : a) the need to avoid cumulative toxicity ; b) the use of drugs which previous trials have shown to be somewhat efficient for the treated tumors (1, 5, 6, 13, 14) ; c) the increase of the percentage of tumor cells destroyed at each therapeutic cycle by the use of drugs which potentialize for cell kinetic reasons (17, 18, 19, 22, 23) and for pharmacodynamic reasons (21).

Keywords

Breast Cancer Sequential Therapy Bronchogenic Carcinoma Total Failure Sequential Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ansfield, F.J.: Current status or 5-fluoro-uracil. Therapy of breast cancer. In Proceedings of the Chemotherapy Conference on the Chemotherapy of Solid Tumors An appraisal of 5-fluoro-uracil and BCNU (S.K. Carter, ed) Washington, January, 1970, p; 48–57.Google Scholar
  2. 2.
    Ansfield, F.J., Corbitz, B.C.and Davis, H.L.Jr.: Five drug therapy for advanced breast cancer. A phase II study. Cancer Chemoth. Rep., 55: 183–194, 1971.Google Scholar
  3. 3.
    Carter, S.K.: Clinical trials and combination chemotherapy. Cancer Chemoth. Rep., 2:81–97, 1971.(part 3 ).Google Scholar
  4. 4.
    Carter, S.K. and Newman, J.W.: 1,3-bis (2-chloroethyl)-1-nitrosoures (NSC-409962,BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosoures (NSC-79037,CCNU). Clinical brochure. Cancer Chemoth. Rep. 1: 115–151, 1968.Google Scholar
  5. 5.
    Cole, M.P., Todd, I.D.H. and Wilkinson, P.M.: Cyclophosphamide and mandrolone deacanoate in the treatment of advanced carcinoma of the breast. Results of a comparative controlled trial of the agents used singly and in combination. Brit. J. Cancer, 27: 396–399, 1973.PubMedCrossRefGoogle Scholar
  6. 6.
    Cooper, R.G.: Combination chemotherapy in hormone resistant breast cancer. Proc. Amer. Ass. Cancer Res., 10: 15, 1969. (abstract)Google Scholar
  7. 7.
    Cooper, R.G.: Five drug combination approach in breast cancer. In-Proceedings of the chemotherapy conference on the chemotherapy of solid tumors. An appraisal of 5-fluoro-uracil and BCNU (S.K. Carter, ed) Washington, January, 1970. p. 149–156.Google Scholar
  8. 8.
    De Vita, V.: Studies at the National Cancer Institute with the nitrosoureas. In Proceedings of the chemotherapy conference on the chemotherapy of solid tumors. An appraisal of 5-fluoro-uracil and BCNU (S.K. Carter, ed) Washington, January 1970, p. 181–188.Google Scholar
  9. 9.
    Goldman, I.D. and Fyfe, M.J.: Free intracellular methotrexate (MTX) is required for maximum inhibition of DNA synthesis augmentation by vincristine (VCR) Proc. Amer. Ass. Cancer Res., 14: 50,1973 (abstract 199)Google Scholar
  10. 10.
    Greenspan, E.: Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. J. Mount Sinai Hosp. N.Y. 33: 1–27, 1966.Google Scholar
  11. 11.
    Hansen, H.H., Muggia, F.M., Andrews, R. and Selawry, O.S.: Intensive combined chemotherapy and radiotherapy in patients with non resectable bronchogenic carcinoma. Cancer 30: 315–324,1972.PubMedCrossRefGoogle Scholar
  12. 12.
    Hansen, H.H., Selawry, O.S., Muggia, F.M. and Walker, M.D.: Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosoures (NSC 79087). Cancer Res., 31: 223–227, 1971.PubMedGoogle Scholar
  13. 13.
    Holland, J.F., Scharlau, C., Gailani, S., Krant, M.J., Olson, K.B., Horton, J., Shnider, B.I., Lynch, J.J. Owens, A., Carbone, P.P., Colsky, J., Grob, D., Miller, S.P. and Hall, T.C. Vincristine. Treatment of advanced cancer. A cooperative study of 392 cases. Cancer Res., 23, 1258–1264, 1973.Google Scholar
  14. 14.
    Horton, J.: Comparison of three weekly dose schedules of 5-fluoro-uracil without a loading dose in the treatment of solid tumors. In Proceedings of the chemotherapy conference on the chemotherapy of solid tumors. An appraisal of 5-fluoro-uracil and BCNU (S.K. Carter, ed) Washington, January, 1970 p. 112–119.Google Scholar
  15. 15.
    Hyde, L., Yee, J., Wilson, R. and Patno, M.E.: Cell cycle and the natural history of lung cancer. J. Amer. Med. Ass. 193: 52–60, 1965.CrossRefGoogle Scholar
  16. 16.
    Jacobs, E.J.: Weekly 5-fluoro-uracil without a loading dose. In Proceedings of the chemotherapy conference on the chemotherapy of solid tumors. An appraisal of 5-fluoro-uracil and BCNU (S.K. Carter, ed) Washington, January 1970, p. 102–111.Google Scholar
  17. 17.
    Klein, O.: Synchronization of tumor cell proliferation and the timing of cytostactic drugs. Europ. J. Clin. Biol. Res. 17: 835–838, 1972.Google Scholar
  18. 18.
    Klein, H.O., Lennartz, K.J., Teichmuller, W. and Gross, R.: Cytostatic treatment of partially synchronized tumor cells in animals and men. VIIth Inter. Congr. or Chemotherapy, Prague, 1971, 1 vol., Munich, Urban und Schwarzenberg, 1972.Google Scholar
  19. 19.
    Mathé, G. and Kenis, Y.: La chimiothérapie des cancers à l’usage du praticien. 3rd. ed., Paris, Expansion Scientifique Frangaise, 1975.Google Scholar
  20. 20.
    Pouillar, P., Hoang Thy Huong, T. and Lheritier, J.: La leucémie L1210, modèle experimental pour la potentialisation des drogues applicables aux leucémies aigües. Bull. Cancer, 61: 509–526, 1974.Google Scholar
  21. 21.
    Pouillart, P., Lheritier, J. and Hoang Thy Huong, T.: Etude expérimentale de la potentialisation pharmacodynamique de drogues anticancéreuses administrees séquentiellement. Biomedicine, 1975, in press.Google Scholar
  22. 22.
    Pouillart, P., Mathe, G. and Schwarzenberg, L.: Essai de recrutement cellulaire par synchronisation partielle pour la combinaison chimiothärapique. Bull. Cancer, 60: 187–196, 1973.Google Scholar
  23. 23.
    Pouillart, P., Schwarzenberg, L., Mathé, G., Schneider, M., Jasmin, C., Hayat, M., Weiner, R., De Vassal, F., Amiel, J.L., Beyer, H.P. and Fajbisowicz, S.: Essai clinique de combinaisons chimiothérapiques basees sur la notion de tentative de synchronisation cellulaire. Nouv. Presse Med., 1, 1757–1762, 1972.PubMedGoogle Scholar
  24. 24.
    Spigel, St. C., Coltman, C.A. and Costanzi, J.J.: Disseminated breast carcinoma: treatment with combination chemotherapy. Arch. Intern. Med. 132, 575–577, 1973.PubMedCrossRefGoogle Scholar
  25. 25.
    Vermund, H.: Radiation and 5-fluoro-uracil in bronchogenic and head cancer. In Proceedings of the chemotherapy conference on the chemotherapy of solid tumors. An appraisal of 5-fluoro-uracil and BCNU (S.K. Carter, Ed), Washington, January 1970, p. 128–135.Google Scholar
  26. 26.
    Walker, M.D.: BCNU therapy of brain tumors. In Proceedings of the chemotherapy conference on the chemotherapy of solid tumors. An appraisal of 5-fluoro-uracil and BCNU (S.K. Carter, ed), Washington, January, 1970,p. 227–235.Google Scholar
  27. 27.
    Walker, M.D. and Hurwitz, B.S.: BCNU (1,3(2-chloroethyl-1-nitrosoures NSC 409962) in the treatment of malignant brain tumor. A preliminary report. Cancer Chemoth. Rep. 54: 263–271, 1970.Google Scholar
  28. 28.
    Wolf, J.: BCNU therapy of Lung cancer. In Proceedings of the chemotherapy conference on the chemotherapy of solid tumors. An appraisal of 5-fluoro-uracil and BCNU (S.K. Carter, ed), Washington, January 1970, p. 203–211.Google Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • P. Pouillart
    • 1
  • L. Schwarzenberg
    • 1
  • J. L. Amiel
    • 1
  • G. Mathé
    • 1
  • P. Huguenin
    • 2
  • Ph. Morin
    • 2
  • A. Baron
    • 2
  • Ch. Laparre
    • 2
  • R. Parrot
    • 2
  1. 1.Unité Fred-Siguier de Développenent Thérapeutique Hôpital Paul Brousse & Service d’Hématologie de l’Institut Gustave RoussVillejuifFrance
  2. 2.Centre Médico-Chirurgical de BlignyBriis-sous-ForgesFrance

Personalised recommendations